Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells

Drugs under Experimental and Clinical Research

Volumn 31, Issue 5-6, 2005, Pages 221-226

  Yamagishi, S ^a   Kikuchi, S ^b   Takenaka, K ^a   Takeuchi, M ^c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CALCIUM ANTAGONIST; CD40 ANTIGEN; CD40 LIGAND; DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE; PROTEIN DERIVATIVE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CD40 GENE; CELL PROTECTION; CHEMICAL INTERACTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; SENESCENCE; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTIGENS, CD40; CALCIUM CHANNEL BLOCKERS; CD40 LIGAND; CELLS, CULTURED; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NIFEDIPINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; UMBILICAL VEINS;

EID: 30144431745     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharm. Res., 23, 129, 2003.
2. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med, 318, 1315, 1988.
3. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem., 266, 11654, 1991.
4. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors. Diabetes Suppl., 3, S65, 1996.
5. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun., 213, 68, 1995
6. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun., 290, 973, 2002.
7. Yamagishi S., Inagaki Y., Amano S., et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
8. Yamagishi S., Okamoto T., Amano S., et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med., 8, 178, 2002.
9. Yamagishi S., Amano S., Inagaki Y., et al. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol. Med., 8, 547, 2002.
10. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 41, 1435, 1998
11. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
12. Yamagishi S., Yonekura H., Yamamoto Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
13. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
14. Okamoto T., Yamagishi S., Inagaki Y., et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem. Biophys Res. Commun., 297, 419, 2002.
15. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309 2002.
16. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int., 63, 464, 2003.
17. Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am. J. Pathol., 150, 523, 1997.
18. Yamagishi S., Nakamura K., Imaizumi T. Adavanced glycation end products (AGEs) and diabetic vascular complications. Curr. Diabetes Rev., 1, 93, 2005.
19. Yamagishi S., Nakamura K , Jinnouchi U., Takenaka K., Imaizumi T. Therapeutic implications of blockers of advanced glycation end products (AGEs) - their receptor (RAGE) system. Int. J Pharm., 1, 203, 2005.
20. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukocyte Biol., 67, 2, 2000.
21. Schonbeck U., Libby P. CD40 signaling and plaque instability. Cir. Res., 89, 1092, 2001.
22. Schonbeck M.F., Libby P. CD40 signaling in vascular cells: A key role in atherosclerosis? Atherosclerosis, 137, S89, 1998.
23. Yamagishi S., Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exptl. Clin. Res., 30, 169, 2004.
24. Ikeda H., Ueyama T., Murohara T., et al. Adhesive interaction between P-selectin and sialyl LewisX plays an important role in recurrent coronary arterial thrombosis in dogs. Arterioscler Thromb. Vasc. Biol., 19, 1083, 1999.
25. Yamagishi S., Takeuchi M. Nifedipine inhibits tumor necrosis factor-α-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells. Drugs Exptl. Clin. Res., 31, 13, 2005.
26. Lee Y., Lee W.H., Lee S.C., et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology, 92, 11, 1999.
27. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature, 394, 200, 1998.
28. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement of CD154 in the progression of atherosclerosis. Nat. Med, 5, 1313, 1999.
29. Yan J., Wu Z. Chen J , Li L., Kong X. Upregulation of CD40-CD40 ligand system in patients with diabetes. Clin. Chem. Acta, 339, 85, 2004.
30. Ramsch K.D., Ziegler R. Plasma concentrations of various nifedipine formulations in healthy volunteers. 6th International Adalat Symposium Excepta Medica, 23, 1986.
31. Fukuo K., Yang J., Yasuda O., et al. Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation, 106, 356, 2002.
32. Wagner A.M., Gebauer M., Pollok-Kopp B., Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood, 99, 520, 2002.
33. Li D., Liu L., Chen H., Sawamura T., Mehta J.L. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscle Throm. Vasc. Biol., 23, 816, 2003
34. Yamagishi S., Inagaki Y., Kikuchi S. Nifedipine inhibits tumor necrosis factor-α-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exptl. Clin. Res., 29, 147, 2003